91 related articles for article (PubMed ID: 20589434)
1. Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.
Rawnaq T; Kunkel M; Bachmann K; Simon R; Zander H; Brandl S; Sauter G; Izbicki JR; Kaifi JT
Ann Surg Oncol; 2011 Feb; 18(2):559-65. PubMed ID: 20589434
[TBL] [Abstract][Full Text] [Related]
2. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
3. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.
Steinert DM; Oyarzo M; Wang X; Choi H; Thall PF; Medeiros LJ; Raymond AK; Benjamin RS; Zhang W; Trent JC
Cancer; 2006 Apr; 106(7):1617-23. PubMed ID: 16518826
[TBL] [Abstract][Full Text] [Related]
4. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
[TBL] [Abstract][Full Text] [Related]
5. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Shen L; Jin ML
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
[TBL] [Abstract][Full Text] [Related]
6. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
Higashi D; Watanabe Y; Hirano K; Shimomura T; Egawa Y; Tomiyasu T; Ishibashi Y; Futami K; Maekawa T; Ota A; Oshige K; Iwashita A
Anticancer Res; 2009 Nov; 29(11):4893-6. PubMed ID: 20032453
[TBL] [Abstract][Full Text] [Related]
7. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
[TBL] [Abstract][Full Text] [Related]
8. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
9. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
Yeh CN; Chen TW; Tseng JH; Liu YY; Wang SY; Tsai CY; Chiang KC; Hwang TL; Jan YY; Chen MF
J Surg Oncol; 2010 Nov; 102(6):599-603. PubMed ID: 20976730
[TBL] [Abstract][Full Text] [Related]
10. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
11. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
Van Glabbeke M; Verweij J; Casali PG; Le Cesne A; Hohenberger P; Ray-Coquard I; Schlemmer M; van Oosterom AT; Goldstein D; Sciot R; Hogendoorn PC; Brown M; Bertulli R; Judson IR
J Clin Oncol; 2005 Aug; 23(24):5795-804. PubMed ID: 16110036
[TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
13. [How should patients with completely resected gastrointestinal stromal tumours (GIST) be followed up?].
Stelzner S; Antoni C; Haroske G; Jacobasch L; Erk JU; Ludwig K
Zentralbl Chir; 2005 Dec; 130(6):554-61. PubMed ID: 16382404
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
Zhu J; Wang Y; Hou M; Li HY; Zhang J
Oncology; 2007; 73(5-6):324-7. PubMed ID: 18497504
[TBL] [Abstract][Full Text] [Related]
15. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
[TBL] [Abstract][Full Text] [Related]
16. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
Benjamin RS; Blanke CD; Blay JY; Bonvalot S; Eisenberg B
Oncologist; 2006 Jan; 11(1):9-20. PubMed ID: 16401709
[TBL] [Abstract][Full Text] [Related]
17. Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study.
Mazzeo F; Duck L; Joosens E; Dirix L; Focan C; Forget F; De Geest S; Muermans K; VAN Lierde MA; Macdonald K; Abraham I; De Grève J
Anticancer Res; 2011 Apr; 31(4):1407-9. PubMed ID: 21508393
[TBL] [Abstract][Full Text] [Related]
18. [Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding].
Siewert E; Tietze L; Maintz C; Geier A; Dietrich CG; Matern S; Gartung C
Z Gastroenterol; 2004 Mar; 42(3):233-42. PubMed ID: 15022111
[TBL] [Abstract][Full Text] [Related]
19. Repeated surgery improves survival in recurrent gastrointestinal stromal tumors: a retrospective analysis of 144 patients.
Schurr P; Kohrs D; Reichelt U; Kaifi J; Vashist Y; Bachmann K; Bogoevski D; Yekebas E; Izbicki J
Dig Surg; 2009; 26(3):229-35. PubMed ID: 19468233
[TBL] [Abstract][Full Text] [Related]
20. Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience.
Armbrust T; Sobotta M; Gunawan B; Füzesi L; Langer C; Cameron S; Ramadori G
Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):819-23. PubMed ID: 19369884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
